Ege Üniversitesi hastanesinde prostat kanserlerinin epidemiyolojisi ve genel sağkalım özellikleri

Amaç: Ege Üniversitesi (EÜ) Hastanesinde 1992-2017 arası kanser tanı ve tedavisi yapılan prostat kanseri (PK) tanılı 4792 hastanın epidemiyolojik özellikleri, tedavi modaliteleri ve sağkalım özelliklerinin tanımlanması amaçlanmıştır. Gereç ve Yöntem: EÜ Kanserle Savaş Araştırma ve Uygulama Merkezi tarafından toplanan PK verileri CANREG özel bilgisayar programına kaydedilmiş, DSÖ (Dünya Sağlık Örgütü) ve SEER (Surveillance, Epidemiolgy, and End Results) sistemleri temelinde gruplanarak analizler yapılmıştır. İstatistiksel analizlerde Kikare, General Linear Model, Kaplan Meier sağkalım analizleri uygulanmıştır. Kaplan-Meier Sağkalım analizinde Log Rank(Mantel-Cox), Breslow(Generalized Wilcoxon) ve TaroneWare istatistikleri kullanılmıştır. İstatistiksel analizlerde p

Epidemiological and overall survival characteristics of prostate cancer in Ege University hospital database

Aim: The aim of this study is to evaluate the epidemiological, treatment modality and survival characteristics of 4792 patients with Prostate Cancer(PC) who were treated at Ege University Hospital (EUH). Materials and Methods: The data were recorded using the CANREG programme. WHO (World Health Organization) and SEER (Surveillance, Epidemiolgy, and End Results) system were considered for classification and survival analysis. Chi-square test, General Linear Model and KaplanMeier survival analysis were done. Log Rank (Mantel-Cox), Breslow (Generalized Wilcoxon) and Tarone-Ware models were used for Kaplan-Meier survival analyses. p value

PDF

___

1. Jemal A, Vineis P, Bray F, Torre L, Forman D (Editörler). Kanser Atlası. İkinci Baskı. Atlanta, GA: Amerikan Kanser Derneği; 2014. www.cancer.org/canceratlas

2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424.

3. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2018. CA Cancer J Clin 2018;68(1):7–30.

4. Ferlay J, Colombet M, Soerjomataram I et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018;103:356-87.

5. Center MM, Jemal A, Lortet-Tieulent J et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61(6):1079–92.

6. Gültekı̇n M, Boztaş G. Türkı̇ye Kanser İstatı̇stı̇klerı̇. TC Sağlık Bakanlığı, Türkiye Halk Sağlığı Kurumu, Kanser Savaş Daire Başkanlığı. 2016.

7. Wong MC, Goggins WB, Wang HH et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol 2016;70(5):862-74.

8. Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol 2018;25(6):524-31.

9. Jeong CW, Washington SL 3rd, Herlemann A, Gomez SL, Carroll PR, Cooperberg MR. The new Surveillance, Epidemiology, and End Results prostate with watchful waiting database: Opportunities and limitations. Eur Urol 2020;21. pii: S0302-2838(20)30045-2.

10. Tınay İ, Türkeri L. Lokalize prostat kanserinde aktif izlem seçeneği. Üroonkolojı̇ Bültenı̇ 2012;11(2): 114-18.

11. van As NJ, Norman AR, Thomas K et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008;54(6): 1297-305.

12.Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol 2010;58(6):831-35.

13. Tosoian JJ, Trock BJ, Landis P et al. Active surveillance program for prostate cancer: An update of the Johns Hopkins experience. J Clin Oncol 2011; 29(16):2185-90.

14.Klotz L, Zhang L, Lam A ve ark. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126-131

15.Knipper S, Pecoraro A, Palumbo, C et al: The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages. Cancer Causes Control 2020;31(3):283-90.